Proceedings of the 2024 Division of Translational Toxicology Satellite Symposium.

The 2024 annual Division of Translational Toxicology (DTT) Satellite Symposium, entitled "Pathology Potpourri," was held in Baltimore, Maryland, at the Society of Toxicologic Pathology's 42nd annual meeting. The goal of this symposium was to present and discuss challenging diagnostic pathology and/or nomenclature issues. This article presents summaries of the speakers' talks along with select images that were used by the audience for voting and discussion.

Concerning Toxic Byproducts and Full-Scale UV/Chlorine Advanced Oxidation Water Treatment.

This work investigated byproduct formation and genotoxicity and cytotoxicity at four facilities using UV/chlorine advanced oxidation for potable reuse or drinking water treatment. In arguably the most common application of UV/chlorine, treating reverse osmosis permeate for potable reuse, organic byproduct formation was always either not detected or well-below typical drinking water levels. At a groundwater-source drinking water treatment plant, the trihalomethanes and haloacetic acids each increased by up to 12 μg/L through the UV reactor and 40 μg/L during secondary disinfection, but the final concentrations remained low relative to regulatory limits.

Remote monitoring of rheumatoid arthritis (REMORA): study protocol for a stepped wedge cluster randomized trial and process evaluation of an integrated symptom tracking intervention.

Background: Management of rheumatoid arthritis (RA) relies on symptoms reported by patients during infrequent outpatient clinic visits. These reports are often incomplete and inaccurate due to poor recall, leading to suboptimal treatment decisions and outcomes. Asking people to track symptoms in-between visits and integrating the data into clinical pathways may improve this.

Mindfulness-based group intervention for adolescents with type 1 diabetes: initial findings from a pilot and feasibility randomized controlled trial.

Objective: To evaluate feasibility/acceptability of a virtual, group mindfulness-based intervention (MBI) adapted for pediatric type 1 diabetes (T1D).

Methods: This two-way controlled trial randomized adolescents 1:1 to MBI (n = 20) or health education (HE; n = 22) groups lasting 6-7 weeks. Eligibility included 12-17 years, T1D ≥ 1 year, and elevated scores on PROMIS depression or anxiety measures.